MedTrace Logo

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)

NCT04752293 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 125

Last updated 2025-12-11

No results posted yet for this study

Summary

Studying the causal roles of components of the renin-angiotensin-aldosterone system (including angiotensin-(1-7) (Ang-(1-7)), angiotensin-converting enzyme 2 (ACE2), Ang II, and ACE), uric acid, and klotho in pediatric hypertension and related target organ injury, including in the heart, kidneys, vasculature, and brain. Recruiting children with a new hypertension diagnosis over a 2-year period from the Hypertension and Pediatric Nephrology Clinics affiliated with Brenner Children's Hospital at Atrium Health Wake Forest Baptist and Atrium Health Levine Children's Hospital. Healthy control participants will be recruited from local general primary care practices. Collecting blood and urine samples to analyze components of the renin-angiotensin-aldosterone system (Ang-(1-7), ACE2, Ang II, ACE), uric acid, and klotho, and measuring blood pressure, heart structure and function, autonomic function, vascular function, and kidney function at baseline, year 1, and year 2. Objectives are to investigate phenotypic and treatment response variability and to causally infer if Ang-(1-7), ACE2, Ang II, ACE, uric acid, and klotho contribute to target organ injury due to hypertension.

Conditions

  • Hypertension
  • Left Ventricular Hypertrophy
  • Left Ventricular Dysfunction
  • Left Atrial Dilatation
  • Left Ventricular Diastolic Dysfunction
  • Kidney Diseases
  • Kidney Injury
  • Kidney Dysfunction
  • Sodium Urine High
  • Blood Pressure Disorders
  • Uric Acid Retention
  • Angiotensin Hypertension
  • Autonomic Dysfunction
  • Autonomic Imbalance
  • Pediatric Kidney Disease
  • Pediatric Obesity
  • Proteinuria
  • Albuminuria

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Andrew M South, MD, MS · Wake Forest Health Sciences

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04752293 on ClinicalTrials.gov